IMCC IM Cannabis Corp. IFRS
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1792030 · Reporting currency CAD · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY1.3%
TTM net income YoY-6.9%
TTM EPS YoY—
Revenue 3-yr CAGR0.2%
Net income 3-yr CAGR—
Margins
Gross margin17.7%
Operating margin-21.2%
Net margin-20.7%
FCF margin8.6%
EBITDA margin—
Returns
ROE-1,496.2%
ROA-31.9%
ROIC (approx.)-63.6%
Asset turnover1.54x
Leverage & solvency
Liabilities / assets111.4%
Debt / equity—
Current ratio0.67x
Interest coverage-3.31x
Cash quality & payout
Operating cash flow / net income-0.42x
Accruals ratio-45.2%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 54.73M | 54.03M | 48.80M | 54.34M | 34.05M |
| Cost of revenue | 45.05M | 45.58M | 37.97M | 43.04M | 25.46M |
| Gross profit | 9.69M | 8.45M | 9.85M | 9.16M | 6.33M |
| SG&A expense | 9.52M | 8.02M | 11.01M | 21.46M | 17.22M |
| Operating income | -11.59M | -10.23M | -12.79M | -30.79M | -23.04M |
| Interest expense | 3.50M | 4.77M | 3.67M | 1.97M | 673,000 |
| Pretax income | -11.66M | -12.79M | -9.46M | -26.06M | -164,000 |
| Income tax | 92,000 | -1.02M | 771,000 | -1.14M | 500,000 |
| Net income | -11.32M | -10.59M | -9.50M | -188.89M | -17.76M |
| EBITDA | — | — | — | -27.98M | -20.91M |
| EPS (basic) | — | -4.51 | -4.45 | -157.83 | -3.06 |
| EPS (diluted) | — | -4.51 | -4.45 | -161.88 | -6.70 |
| Weighted avg. shares (diluted) | — | — | 12.82M | 7.49M | 5.98M |
| Balance sheet | |||||
| Cash & equivalents | 2.73M | 863,000 | 1.81M | 2.45M | 13.90M |
| Short-term investments | — | — | — | — | 3.13M |
| Receivables | 4.32M | 5.42M | 4.83M | 3.32M | 14.48M |
| Inventory | 4.27M | 3.21M | 9.98M | 16.59M | 29.39M |
| Current assets | 22.74M | 23.36M | 24.27M | 32.67M | 81.18M |
| PP&E, netmay include right-of-use assets (IFRS) | 3.71M | 3.73M | 5.06M | 5.22M | 30.27M |
| Goodwill | 1.89M | 6.68M | 10.10M | 9.77M | 121.30M |
| Intangibles | 1.22M | 3.33M | 5.80M | 7.91M | 30.89M |
| Total assets | 31.74M | 39.19M | 48.81M | 60.68M | 287.39M |
| Current liabilities | 34.01M | 34.92M | 32.85M | 33.82M | 51.23M |
| Short-term debt | 14.33M | 15.14M | 12.12M | 9.25M | 9.50M |
| Long-term debt | 936,000 | 466,000 | 394,000 | 399,000 | 392,000 |
| Total debt | 15.27M | 15.61M | 12.51M | 9.64M | 9.89M |
| Total liabilities | 35.35M | 36.04M | 35.11M | 36.88M | 82.44M |
| Shareholders' equity | -3.73M | 5.24M | 14.47M | 22.65M | 201.24M |
| Net debt | 12.54M | 14.75M | 10.70M | 7.20M | -4.01M |
| Shares outstanding | 5.89M | 3.09M | 2.23M | 1.26M | 1.14M |
| Cash flow statement | |||||
| Operating cash flow | 4.72M | -1.08M | -8.07M | -12.64M | -34.37M |
| Capital expenditure | 13,000 | 156,000 | 581,000 | 1.56M | 4.58M |
| Free cash flow | 4.70M | -1.23M | -8.66M | -14.20M | -38.95M |
| Investing cash flow | -531,000 | -470,000 | -1.18M | -1.53M | -9.01M |
| Financing cash flow | 1.15M | 3.83M | 9.42M | 4.76M | 48.73M |
| Depreciation & amortization | — | — | — | 2.81M | 2.12M |
| Stock-based compensation | 14,000 | 369,000 | 225,000 | 3.77M | 7.47M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.